“mannkind”

Stock Nucleus

Stock Nucleus Providing Stock Market and Public Company Information SearchADS Wednesday, January 26, 2011 What Will Happen to Mannkind? The FDA has sent MNKD a complete response letter for Affrezza asking for 2 more trials. The trial will involve type 1 and type 2 diabetics and the goal is to compare Mannkind?s new inhaler to the original inhaler that was used in prior studies. If MNKD can complete the trials Affrezza has a great chance at being approved by the FDA. During the conference